Addressing gaps in care and insights
Dermatology conditions affect millions of patients and result in hundreds of millions of dollars in loss of productivity every year. Yet, despite increased development of new treatments, high quality research-driven insights to enable market adoption, understand safety and effectiveness profiles, broaden payer coverage, and increase access to care are lacking or have been difficult to attain.
Dermatologic conditions are complex. Accessing data shouldn’t be.
Understanding the complexities of these diseases, how they relate to other co-morbid conditions, and their impact on different patient populations requires a dynamic new approach to dermatology data curation.
Meet the largest dermatology data network in the U.S.
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to support your programs shouldn’t be. That’s why OM1 and the American Academy of Dermatology joined forces in connecting the DataDerm™ Registry with the OM1 Real-World Data Cloud. Together, we’ve built the largest dermatology network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
AD patients with deep clinical data
Psoriasis patients with deep clinical data
Psoriatic Arthritis patients with deep clinical data
*Data counts as of Q1 2022 ©OM1 Dermatology Specialty Area
From evidence to insights
How we can help
Our specialized data and tools provide access to longitudinal patient journeys, and critical outcomes and endpoints, to enable rapid and more in-depth analyses.
Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.
Measure key safety outcomes of interest and support regulatory requirements such as monitoring and comparing the real-world safety profiles for patients on JAK Inhibitors.
Align with real world-based patient behaviors to measure adherence to novel treatment approaches such as for atopic dermatitis.
Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, assess the cost effectiveness of early treatment interventions for psoriatic arthritis.
RWD can help guide planning, forecasting, and improving brand performance such as understanding the size of the market by segment in PsO patient subtypes that are best aligned with a brand’s positioning.
Meet our dermatology expert
Stefan C. Weiss, MD is the Managing Director of Dermatology at OM1. A leader in the field of dermatology, his career has spanned both health care delivery and life sciences. Previously, he was Senior Medical Director at a publicly held dermatology focused biotech during which time he secured multiple new drug approvals for the treatment of inflammatory skin diseases.
Dr. Weiss is a board certified dermatologist. He has served on several national medical advisory committees and has published widely on psoriasis and atopic dermatitis.
Dr. Weiss is a graduate of Yale University. He received his MD and MHSc in Clinical Research from the Duke University School of Medicine. He completed residency training in dermatology at the Stanford University School of Medicine and a fellowship in Bioethics at the NIH. He holds an MBA from the Kellogg School of Management at Northwestern University.